Scarica l'app Stockscreener
3.88
0.77%
-0.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ESPR Giù?
Forum
Previsione
Frazionamento azionario
Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie
Can Esperion Therapeutics Inc. stock sustain institutional interest2025 Market Sentiment & AI Driven Price Predictions - ulpravda.ru
Will Esperion Therapeutics Inc. (0ET) stock beat growth indexesQuarterly Performance Summary & Trade Opportunity Analysis - ulpravda.ru
Merger Talk: Is Esperion Therapeutics Inc. (0ET) stock considered safe haven2025 Winners & Losers & Reliable Momentum Entry Alerts - ulpravda.ru
Esperion Therapeutics gets Untitled Letter from FDA over Nexlizet ad - Medical Marketing and Media
How Esperion Therapeutics Inc. stock performs in rising dollar environmentQuarterly Profit Report & Technical Buy Zone Confirmations - ulpravda.ru
Free Technical Research Reports on Biotech Stocks -- Epizyme, Esperion Therapeutics, Exelixis, and Grifols - ADVFN
Will Esperion Therapeutics Inc. (0ET) stock outperform value peersVolume Profile Analysis & Double Digit Returns - ulpravda.ru
Esperion Sets Its Sights on New Areas While Maintaining Commitment to Cardiovascular Health - MedCity News
Esperion Therapeutics chief commercial officer sells $277 in stock - MSN
Esperion to Participate in Upcoming 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
What analysts say about Esperion Therapeutics Inc stockMarket Volatility Update & Rapid Wealth Accumulation - earlytimes.in
Why Is Esperion Therapeutics Stock Sinking Premarket Today? - MSN
Esperion Therapeutics (NASDAQ:ESPR) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap UpWhat's Next? - MarketBeat
Is Esperion Therapeutics Inc a good long term investmentGlobal Trade Effects & Free Rapid Wealth Building - earlytimes.in
Esperion Therapeutics (NASDAQ:ESPR) Shares Down 4.8%Time to Sell? - MarketBeat
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
PFE6265887 Bond Coupon Analysis — Rate & Payments - TradingView — Track All Markets
Esperion Therapeutics (NASDAQ:ESPR) Hits New 52-Week HighTime to Buy? - MarketBeat
Is Esperion Therapeutics Inc. stock attractive for long term wealth buildingPortfolio Update Summary & Real-Time Volume Triggers - Улправда
Will Esperion Therapeutics Inc. stock split attract more investorsJuly 2025 Intraday Action & Weekly High Return Stock Forecasts - DonanımHaber
How Esperion Therapeutics Inc. (0ET) stock compares with top peersQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - DonanımHaber
Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes - The Manila Times
Esperion's Bempedoic Acid Recognized by ACC as Effective LDL-C Lowering Therapy for Patients with PAD and Diabetes - Quiver Quantitative
Esperion’s Bempedoic Acid Receives Recommendation in 2025 - GlobeNewswire
Take Profit: Will Esperion Therapeutics Inc. stock maintain momentum in 2025 - DonanımHaber
Can Esperion Therapeutics Inc. stock hit record highs againJuly 2025 Macro Moves & AI Powered Market Entry Strategies - Улправда
Esperion Therapeutics Q3 2025 Earnings Preview - MSN
[Form 4] Esperion Therapeutics, Inc. Insider Trading Activity - Stock Titan
Esperion Therapeutics (ESPR) CEO files Form 4 for 48,244-share tax sale - Stock Titan
Esperion Therapeutics (NASDAQ:ESPR) General Counsel Sells $23,917.39 in Stock - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) CFO Benjamin Halladay Sells 7,337 Shares - MarketBeat
Esperion Therapeutics Executives Sell Shares to Satisfy Tax Obligations - TradingView — Track All Markets
CFO Halladay Surrenders 7,337 Of Esperion Therapeutics Inc [ESPR] - TradingView — Track All Markets
Esperion Therapeutics (ESPR) CFO reports 7,337-share sale for tax obligations - Stock Titan
Officer Looker Files To Sell 6,517 Of Esperion Therapeutics Inc [ESPR] - TradingView — Track All Markets
PFE6265887 Bond Analysis — Key Metrics - TradingView — Track All Markets
Investors Purchase High Volume of Call Options on Esperion Therapeutics (NASDAQ:ESPR) - MarketBeat
Esperion Therapeutics (NASDAQ:ESPR) Sets New 12-Month HighShould You Buy? - MarketBeat
Esperion’s Stock Surge: Opportunity Knocks? - StocksToTrade
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Sahm
Why The Narrative Around Esperion Therapeutics Is Shifting After Analyst Upgrades And Trial Results - Yahoo Finance
Esperion announces inducement grants under Nasdaq Listing Rule - marketscreener.com
Esperion Grants Stock Options and RSUs to New Chief Commercial Officer and Employees - Quiver Quantitative
Esperion Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Two Seas Capital LP Raises Holdings in Esperion Therapeutics, Inc. $ESPR - MarketBeat
Will Esperion Therapeutics Inc. (0ET) stock enhance shareholder valueEarnings Overview Summary & Smart Money Movement Alerts - Newser
Esperion stock hits fair value target with 77% gain since April 2024 - Investing.com Australia
Esperion Therapeutics, Inc.Common Stock (Nasdaq:ESPR) Stock Quote - Markets Financial Content
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Is Esperion Therapeutics Inc. (0ET) stock a top dividend aristocrat candidateTrend Reversal & Stepwise Trade Execution Plans - Newser
ESPR SEC FilingsEsperion Therape 10-K, 10-Q, 8-K Forms - Stock Titan
Esperion Therapeutics (NASDAQ:ESPR) Trading 6% HigherHere's What Happened - MarketBeat
Esperion a new overweight at Piper Sandler on CV franchise - MSN
0.37%
1.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):